Archives — October 2017 back to current month (12)

Biopharmaceutical Firm Receives FDA Priority Review and PDUFA Date (10/25/2017)

Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics.

more>

Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity' (10/25/2017)

Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease.

more>

Coverage Initiated on Gene Therapy Company (10/25/2017)

Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe.

more>

Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY (10/25/2017)

Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system.

more>

Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference (10/18/2017)

Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting.

more>

Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials (10/18/2017)

With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia.

more>

Reliq Health Technologies Quickly Gaining Traction in Fast Growing Telemedicine Market (10/11/2017)

The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, and Reliq Health Technologies is adding thousands of patients to its rolls.

more>

Cannabis Company Forms Partnership to Develop Pharmaceuticals (10/06/2017)

Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor.

more>

Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market (10/05/2017)

The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market.

more>

Reliq Health Technologies Quickly Gaining Traction in Rapidly Growing Telemedicine Market (10/05/2017)

The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market.

more>

Japan Is Fertile Ground for Biotech Deals (10/04/2017)

Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness.

more>

Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia (10/04/2017)

A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.

more>

More Archives

2017Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

Notable Quotes

"RXII's sd-rxRNA can augment already amazing results in immunotherapy."
– John Vandermosten, Zacks Small-Cap Research
"We are initiating coverage on RVX with a Buy rating."
– David Kideckel, Beacon Securities Ltd.